ZNF839 Inhibitors
ZNF839 inhibitors encompass a group of chemicals that target various biochemical pathways to indirectly suppress the functional activity of ZNF839. One such mechanism includes the inhibition of protein kinases, which are crucial for phosphorylation processes that ZNF839 may rely on to perform DNA binding and transcription regulation. Another mechanism involves the inhibition of proteasomes, which are responsible for the degradation of ubiquitinated proteins; by blocking this pathway, the regulated proteolysis that ZNF839 may need for functional cycling is disrupted. Furthermore, compounds that inhibit the PI3K/AKT pathway or the MAPK/ERK pathway can have a downstream effect, altering the cellular environment and phosphorylation status that could affect ZNF839's activity. Similarly, the inhibition of p38 MAPK or JNK can prevent the activation of transcription factors that might be necessary for the expression of ZNF839, thus leading to its functional inhibition.
Additionally, certain inhibitors target the synthesis of proteins, which could decrease the levels of ZNF839 in the cell. For instance, mTOR inhibition can impair protein synthesis, while other compounds that interfere with the translocation step in protein synthesis directly reduce ZNF839 levels. Changes in gene expression patterns are also a target, with HDAC inhibitors potentially downregulating ZNF839 expression by altering chromatin structure. DNA methyltransferase inhibitors can induce hypomethylation of DNA, leading to changes in gene expression that may decrease ZNF839 activity. Moreover, the disruption of normal proteostasis by proteasome inhibitors could affect the folding and function of ZNF839. Lastly, cyclin-dependent kinase inhibitors can impede cell cycle progression and transcription factor activity, which could result in decreased expression andactivity of ZNF839.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which can lead to the suppression of kinase-mediated phosphorylation necessary for the function of ZNF839 in processes such as DNA binding and transcription regulation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins, potentially leading to reduced activity of ZNF839 by disrupting its regulated proteolysis, which could be essential for its functional cycling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor that can disrupt the PI3K/AKT pathway, which is involved in the regulation of numerous proteins, including zinc finger proteins like ZNF839, thus indirectly inhibiting its function by altering the cellular environment. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that can affect the MAPK/ERK pathway. Since zinc finger proteins can be regulated by phosphorylation through this pathway, ZNF839's activity could be indirectly inhibited. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor, which could prevent the activation of transcription factors that are potentially necessary for the expression of ZNF839. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which may reduce the activity of transcription factors that regulate the expression of ZNF839, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the signaling pathway that controls protein synthesis. Inhibiting mTOR could decrease the synthesis of proteins like ZNF839. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in protein synthesis, potentially reducing the levels of ZNF839 in the cell. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs), which can alter chromatin structure and gene expression, potentially leading to the downregulation of ZNF839 expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor, which can lead to the hypomethylation of DNA and subsequent changes in gene expression, possibly resulting in decreased ZNF839 activity. | ||||||